Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Dysplasia 1 Oligodendroglioma 1 Neoplasms 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Temozolomide 88 Bevacizumab 49 Radiotherapy 36 Irinotecan 22 Magnetic Resonance Spectroscopy 21 Surgical Procedures, Operative 17 Carboplatin 17 Carmustine 15 Radiation 13 Nivolumab 11 IL13-PE38 8 Erlotinib Hydrochloride 8 Thalidomide 7 Radiotherapy, Intensity-Modulated 7 Lomustine 7 Imatinib Mesylate 7 Everolimus 7 Aminolevulinic Acid 7 sargramostim 6 Topotecan 6 O(6)-benzylguanine 6 Cyclophosphamide 6 Chemotherapy, Adjuvant 6 vandetanib 5 temsirolimus 5 fluorodopa F 18 5 Vincristine 5 Surveys and Questionnaires 5 Radiosurgery 5 Flucytosine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Glioma × terameprocol × Clear all

NCT02575794 2023-10-06

Terameprocol in Treating Patients With Recurrent High Grade Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡